|
1
|
Davies C, Godwin J, Gray R, et al:
Relevance of breast cancer hormone receptors and other factors to
the efficacy of adjuvant tamoxifen: patient-level meta-analysis of
randomised trials. Lancet. 378:771–784. 2011. View Article : Google Scholar
|
|
2
|
Dutertre M and Smith CL: Molecular
mechanisms of selective estrogen receptor modulator (SERM) action.
J Pharmacol Exp Ther. 295:431–437. 2000.PubMed/NCBI
|
|
3
|
Thrane S, Lykkesfeldt AE, Larsen MS,
Sorensen BS and Yde CW: Estrogen receptor alpha is the major
driving factor for growth in tamoxifen-resistant breast cancer and
supported by HER/ERK signaling. Breast Cancer Res Treat. 139:71–80.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lavinsky RM, Jepsen K, Heinzel T, et al:
Diverse signaling pathways modulate nuclear receptor recruitment of
N-CoR and SMRT complexes. Proc Natl Acad Sci USA. 95:2920–2925.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hurtado A, Holmes KA, Ross-Innes CS,
Schmidt D and Carroll JS: FOXA1 is a key determinant of estrogen
receptor function and endocrine response. Nat Genet. 43:27–33.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xu J and Li Q: Review of the in vivo
functions of the p160 steroid receptor coactivator family. Mol
Endocrinol. 17:1681–1692. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Font de Mora J and Brown M: AIB1 is a
conduit for kinase-mediated growth factor signaling to the estrogen
receptor. Mol Cell Biol. 20:5041–5047. 2000.PubMed/NCBI
|
|
8
|
Bunone G, Briand PA, Miksicek RJ and
Picard D: Activation of the unliganded estrogen receptor by EGF
involves the MAP kinase pathway and direct phosphorylation. EMBO J.
15:2174–2183. 1996.PubMed/NCBI
|
|
9
|
Kato S, Endoh H, Masuhiro Y, et al:
Activation of the estrogen receptor through phosphorylation by
mitogen-activated protein kinase. Science. 270:1491–1494. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Campbell RA, Bhat-Nakshatri P, Patel NM,
Constantinidou D, Ali S and Nakshatri H: Phosphatidylinositol
3-kinase/ AKT-mediated activation of estrogen receptor alpha: a new
model for anti-estrogen resistance. J Biol Chem. 276:9817–9824.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zwick E, Bange J and Ullrich A: Receptor
tyrosine kinase signalling as a target for cancer intervention
strategies. Endocr Relat Cancer. 8:161–173. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wilhelm SM, Adnane L, Newell P, Villanueva
A, Llovet JM and Lynch M: Preclinical overview of sorafenib, a
multikinase inhibitor that targets both Raf and VEGF and PDGF
receptor tyrosine kinase signaling. Mol Cancer Ther. 7:3129–3140.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Plaza-Menacho I, Morandi A, Robertson D,
et al: Targeting the receptor tyrosine kinase RET sensitizes breast
cancer cells to tamoxifen treatment and reveals a role for RET in
endocrine resistance. Oncogene. 29:4648–4657. 2010. View Article : Google Scholar
|
|
14
|
Escudier B, Eisen T, Stadler WM, et al:
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J
Med. 356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Llovet JM, Ricci S, Mazzaferro V, et al:
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med.
359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Luu T, Frankel P, Chung C, et al: Phase
I/II trial of vinorelbine and sorafenib in metastatic breast
cancer. Clin Breast Cancer. 14:94–100. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Baselga J, Costa F, Gomez H, et al: A
phase 3 trial comparing capecitabine in combination with sorafenib
or placebo for treatment of locally advanced or metastatic
HER2-negative breast cancer (the RESILIENCE study): study protocol
for a randomized controlled trial. Trials. 14:2282013. View Article : Google Scholar
|
|
18
|
Wilhelm SM, Carter C, Tang L, et al: BAY
43-9006 exhibits broad spectrum oral antitumor activity and targets
the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in
tumor progression and angiogenesis. Cancer Res. 64:7099–7109. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Weisberg E, Manley P, Mestan J,
Cowan-Jacob S, Ray A and Griffin JD: AMN107 (nilotinib): a novel
and selective inhibitor of BCR-ABL. Br J Cancer. 94:1765–1769.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
O’Hare T, Walters DK, Deininger MW and
Druker BJ: AMN107: tightening the grip of imatinib. Cancer Cell.
7:117–119. 2005.PubMed/NCBI
|
|
21
|
Piccaluga PP, Paolini S, Bertuzzi C, De
Leo A and Rosti G: First-line treatment of chronic myeloid leukemia
with nilotinib: critical evaluation. J Blood Med. 3:151–156. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Weigel MT, Ghazoui Z, Dunbier A, Pancholi
S, Dowsett M and Martin LA: Preclinical and clinical studies of
estrogen deprivation support the PDGF/Abl pathway as a novel
therapeutic target for overcoming endocrine resistance in breast
cancer. Breast Cancer Res. 14:R782012. View
Article : Google Scholar
|
|
23
|
Briand P and Lykkesfeldt AE: Effect of
estrogen and antiestrogen on the human breast cancer cell line
MCF-7 adapted to growth at low serum concentration. Cancer Res.
44:1114–1119. 1984.PubMed/NCBI
|
|
24
|
Lykkesfeldt AE, Madsen MW and Briand P:
Altered expression of estrogen-regulated genes in a
tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human
breast cancer cell line, MCF-7/TAMR-1. Cancer Res.
54:1587–1595. 1994.PubMed/NCBI
|
|
25
|
Lundholt BK, Briand P and Lykkesfeldt AE:
Growth inhibition and growth stimulation by estradiol of estrogen
receptor transfected human breast epithelial cell lines involve
different pathways. Breast Cancer Res Treat. 67:199–214. 2001.
View Article : Google Scholar
|
|
26
|
Larsen MS, Yde CW, Christensen IJ and
Lykkesfeldt AE: Carboplatin treatment of antiestrogen-resistant
breast cancer cells. Int J Oncol. 41:1863–1870. 2012.
|
|
27
|
Arnold SF, Obourn JD, Jaffe H and Notides
AC: Phosphorylation of the human estrogen receptor by
mitogen-activated protein kinase and casein kinase II: consequence
on DNA binding. J Steroid Biochem Mol Biol. 55:163–172. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
De Leeuw R, Neefjes J and Michalides R: A
role for estrogen receptor phosphorylation in the resistance to
tamoxifen. Int J Breast Cancer. 2011:2324352011.PubMed/NCBI
|
|
29
|
Chen D, Riedl T, Washbrook E, et al:
Activation of estrogen receptor alpha by S118 phosphorylation
involves a ligand-dependent interaction with TFIIH and
participation of CDK7. Mol Cell. 6:127–137. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wijayaratne AL and McDonnell DP: The human
estrogen receptor-alpha is a ubiquitinated protein whose stability
is affected differentially by agonists, antagonists, and selective
estrogen receptor modulators. J Biol Chem. 276:35684–35692. 2001.
View Article : Google Scholar
|
|
31
|
Osborne CK, Wakeling A and Nicholson RI:
Fulvestrant: an oestrogen receptor antagonist with a novel
mechanism of action. Br J Cancer. 90(Suppl 1): S2–S6. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kroemer G and Jaattela M: Lysosomes and
autophagy in cell death control. Nat Rev Cancer. 5:886–897. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shou J, Massarweh S, Osborne CK, et al:
Mechanisms of tamoxifen resistance: increased estrogen
receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J
Natl Cancer Inst. 96:926–935. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hodges LC, Cook JD, Lobenhofer EK, et al:
Tamoxifen functions as a molecular agonist inducing cell
cycle-associated genes in breast cancer cells. Mol Cancer Res.
1:300–311. 2003.PubMed/NCBI
|
|
35
|
Vendrell JA, Bieche I, Desmetz C, et al:
Molecular changes associated with the agonist activity of
hydroxy-tamoxifen and the hyper-response to estradiol in
hydroxy-tamoxifen-resistant breast cancer cell lines. Endocr Relat
Cancer. 12:75–92. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Osborne CK, Bardou V, Hopp TA, et al: Role
of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in
tamoxifen resistance in breast cancer. J Natl Cancer Inst.
95:353–361. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Su Q, Hu S, Gao H, et al: Role of AIB1 for
tamoxifen resistance in estrogen receptor-positive breast cancer
cells. Oncology. 75:159–168. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Smith CL, Nawaz Z and O’Malley BW:
Coactivator and corepressor regulation of the agonist/antagonist
activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol
Endocrinol. 11:657–666. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Reiter R, Oh AS, Wellstein A and Riegel
AT: Impact of the nuclear receptor coactivator AIB1 isoform
AIB1-Delta3 on estrogenic ligands with different intrinsic
activity. Oncogene. 23:403–409. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Rahmani M, Davis EM, Crabtree TR, et al:
The kinase inhibitor sorafenib induces cell death through a process
involving induction of endoplasmic reticulum stress. Mol Cell Biol.
27:5499–5513. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Liu L, Cao Y, Chen C, et al: Sorafenib
blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and
induces tumor cell apoptosis in hepatocellular carcinoma model
PLC/PRF/5. Cancer Res. 66:11851–11858. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Shaker ME, Ghani A, Shiha GE, Ibrahim TM
and Mehal WZ: Nilotinib induces apoptosis and autophagic cell death
of activated hepatic stellate cells via inhibition of histone
deacetylases. Biochim Biophys Acta. 1833:1992–2003. 2013.
View Article : Google Scholar : PubMed/NCBI
|
